Roche (RHHBF) unit Genentech posts encouraging late-stage trial data for its breast cancer drug giredestrant noting up to 62% ...

Abemaciclib plus endocrine therapy significantly improves overall survival in high-risk early breast cancer, reducing death risk by 15.8% compared to endocrine therapy alone.

In "We Survived the Night," NoiseCat touches on family history, community, and Indigenous life across North America.

Looking for the latest Endless Horde codes? We’ve got you covered! This list includes all of the active… The post Endless Horde Codes – October 2025 first appeared on PowerUp Gamer.

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free ...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard- ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer ...

Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a ...

For children born with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), an investigational ...

Alpha Prime is a sci-fi shooter from Black Element Software. Explore an abandoned asteroid, fight robots, survive in space ...

Imfinzi plus FLOT chemotherapy significantly improves overall survival in resectable G/GEJ adenocarcinoma compared to placebo ...

BERLIN -- Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly ...